(DCGO) DocGo - Ratings and Ratios
Mobile Healthcare, Diagnostics, Transportation, Remote Monitoring
DCGO EPS (Earnings per Share)
DCGO Revenue
Description: DCGO DocGo
DocGo Inc (NASDAQ:DCGO) is a US-based company operating in the Health Care Equipment sub-industry. To understand the companys financial health, we need to examine its income statement, particularly the Income Tax Expense on a yearly basis.
The absence of a reported P/E ratio and RoE suggests that the company may be currently unprofitable, which is not uncommon for growth-stage companies in the healthcare sector. However, the forward P/E ratio of 60.24 indicates that investors are expecting significant future earnings growth. We need to assess whether this expectation is justified by analyzing the companys key drivers, such as revenue growth, operating margins, and cash flow generation.
To evaluate DCGOs performance, we should focus on key performance indicators (KPIs) like revenue growth rate, gross margin expansion, and operating expense management. Additionally, we need to consider the economic drivers influencing the healthcare equipment industry, including government regulations, technological advancements, and demographic trends. For instance, an aging population and an increased focus on healthcare infrastructure may drive demand for DCGOs services.
A critical analysis of DCGOs financials and industry dynamics is necessary to determine whether the current stock price reflects the companys true value. With a market capitalization of $162.36M USD and an average trading volume of 484,427 shares, liquidity is relatively moderate. We must now examine the companys business model, competitive positioning, and growth prospects to inform our investment decision.
DCGO Stock Overview
| Market Cap in USD | 152m |
| Sub-Industry | Health Care Equipment |
| IPO / Inception | 2021-11-05 |
DCGO Stock Ratings
| Growth Rating | -86.7% |
| Fundamental | 36.9% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -65.0% |
| Analyst Rating | 4.0 of 5 |
DCGO Dividends
Currently no dividends paidDCGO Growth Ratios
| Growth Correlation 3m | 5.1% |
| Growth Correlation 12m | -76.8% |
| Growth Correlation 5y | -87.2% |
| CAGR 5y | -46.71% |
| CAGR/Max DD 3y | -0.53 |
| CAGR/Mean DD 3y | -0.76 |
| Sharpe Ratio 12m | -0.06 |
| Alpha | 0.00 |
| Beta | 0.915 |
| Volatility | 62.19% |
| Current Volume | 214.5k |
| Average Volume 20d | 299.3k |
| Stop Loss | 1.3 (-12.2%) |
| Signal | -1.74 |
Piotroski VR‑10 (Strict, 0-10) 2.0
| Net Income (-18.3m TTM) > 0 and > 6% of Revenue (6% = 26.2m TTM) |
| FCFTA 0.0 (>2.0%) and ΔFCFTA 15.23pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 31.3m% (prev 23.50%; Δ 31.3mpp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.00 (>3.0%) and CFO 87.2m > Net Income -18.3m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 2.36 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (98.9m) change vs 12m ago -6.95% (target <= -2.0% for YES) |
| Gross Margin -12.6m% (prev 31.84%; Δ -12.6mpp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 0.00% (prev 152.2%; Δ -152.2pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -14.48 (EBITDA TTM -12.5m / Interest Expense TTM 1.92m) >= 6 (WARN >= 3) |
Altman Z'' 1.85
| (A) 0.33 = (Total Current Assets 236574.63b - Total Current Liabilities 100146.64b) / Total Assets 408263.75b |
| (B) -0.05 = Retained Earnings (Balance) -21962.73b / Total Assets 408263.75b |
| (C) -0.00 = EBIT TTM -27.7m / Avg Total Assets 204132.12b |
| (D) -0.16 = Book Value of Equity -19231.35b / Total Liabilities 120533.02b |
| Total Rating: 1.85 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 36.90
| 1. Piotroski 2.0pt = -3.0 |
| 2. FCF Yield data missing |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.07 = 2.50 |
| 5. Debt/Ebitda data missing |
| 6. ROIC - WACC (= -8.08)% = -10.11 |
| 7. RoE -0.00% = -0.00 |
| 8. Rev. Trend -14.64% = -1.10 |
| 9. EPS Trend -27.85% = -1.39 |
What is the price of DCGO shares?
Over the past week, the price has changed by -1.99%, over one month by -11.90%, over three months by -7.50% and over the past year by -58.54%.
Is DocGo a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of DCGO is around 0.79 USD . This means that DCGO is currently overvalued and has a potential downside of -46.62%.
Is DCGO a buy, sell or hold?
- Strong Buy: 3
- Buy: 1
- Hold: 3
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the DCGO price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 3.1 | 108.1% |
| Analysts Target Price | 3.1 | 108.1% |
| ValueRay Target Price | 0.9 | -39.9% |
Last update: 2025-09-05 04:39
DCGO Fundamental Data Overview
CCE Cash And Equivalents = 108554.57b USD (Cash And Short Term Investments, last quarter)
P/E Forward = 60.241
P/S = 0.3477
P/B = 0.5116
Beta = 0.963
Revenue TTM = 436.0m USD
EBIT TTM = -27.7m USD
EBITDA TTM = -12.5m USD
Long Term Debt = 20386.38b USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 40.1m USD (from shortTermDebt, last quarter)
Debt = 20386.42b USD (Calculated: Short Term 40.1m + Long Term 20386.38b)
Net Debt = -48102.24b USD (from netDebt column, last quarter)
Enterprise Value = -88168.00b USD (151.6m + Debt 20386.42b - CCE 108554.57b)
Interest Coverage Ratio = -14.48 (Ebit TTM -27.7m / Interest Expense TTM 1.92m)
FCF Yield = none (FCF TTM 0.0 / Enterprise Value -88168.00b)
FCF Margin = unknown (0.0 / 435968564.0)
Net Margin = -4.20% (Net Income TTM -18.3m / Revenue TTM 436.0m)
Gross Margin = -12.6m% ((Revenue TTM 436.0m - Cost of Revenue TTM 54998.76b) / Revenue TTM)
Tobins Q-Ratio = 4.58 (Enterprise Value -88168.00b / Book Value Of Equity -19231.35b)
Interest Expense / Debt = 0.00% (Interest Expense 443.7k / Debt 20386.42b)
Taxrate = 51.85% (14.4m / 27.7m)
NOPAT = -27.7m (EBIT -27.7m, no tax applied on loss)
Current Ratio = 2.36 (Total Current Assets 236574.63b / Total Current Liabilities 100146.64b)
Debt / Equity = 0.07 (Debt 20386.42b / last Quarter total Stockholder Equity 297277.71b)
Debt / EBITDA = -1.63m (Net Debt -48102.24b / EBITDA -12.5m)
Debt / EBITDA = -1.63m --> set to None
Debt / FCF = none (Debt 20386.42b / FCF TTM 0.0)
Total Stockholder Equity = 74319.67b (last 4 quarters mean)
RoA = -0.00% (Net Income -18.3m, Total Assets 408263.75b )
RoE = -0.00% (Net Income TTM -18.3m / Total Stockholder Equity 74319.67b)
RoCE = -0.00% (Ebit -27.7m / (Equity 74319.67b + L.T.Debt 20386.38b))
RoIC = -8.08% (NOPAT -27.7m / Invested Capital 343.2m)
WACC = 0.00% (E(151.6m)/V(20386.57b) * Re(9.39%)) + (D(20386.42b)/V(20386.57b) * Rd(0.00%) * (1-Tc(0.52)))
Shares Correlation 3-Years: -21.21 | Cagr: -0.74%
Discount Rate = 9.39% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow 0.0)
EPS Correlation: -27.85 | EPS CAGR: -70.61% | SUE: -1.30 | # QB: 0
Revenue Correlation: -14.64 | Revenue CAGR: -9.03% | SUE: 0.21 | # QB: 0
Additional Sources for DCGO Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle